Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension
Information source: Abbott
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Tarka (trandolapril/verapamil) (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Abbott Official(s) and/or principal investigator(s):
Victor Gorin, MD, Study Director, Affiliation: Abbott
Summary
This study will investigate antihypertensive activity and safety profile of Tarka in Russian
hypertension patients by ambulatory blood pressure measurement (ABPM)
Clinical Details
Official title: A Multicenter, Open, Phase IV, 24-Hour Ambulatory Blood Pressure Monitoring Study of the Efficacy and Safety of Tarka in Patients With Arterial Hypertension
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Change in blood pressure from baseline/blood pressure control
Secondary outcome: Absolute BP reduction from baseline, safety
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Hypertension
Exclusion Criteria:
- SBP > 180 mm Hg, DBP > 114 mm Hg
- Subject has a hypersensitivity to trandolapril or verapamil
Locations and Contacts
Global Medical Information-Abbott, North Chicago, Illinois 60064, United States
Additional Information
Starting date: June 2004
Last updated: August 30, 2007
|
